Guard therapeutics

The Guard therapeutics conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC

Guard therapeutics

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Acute kidney injury is a large market. Guard Therapeutics announced that the U. Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of Financial calender Financial reports Share information Corporate governance General meetings. Press releases Event calender Analyses and presentations In media Subscribe. Latest Press Releases. Read more. Guard Therapeutics receives media attention after research view by Danske Bank Read more.

Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, guard therapeutics, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients guard therapeutics are at increased risk for acute kidney injury.

.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. New preclinical results from the company's peptide platform will also be presented. The next developmental step includes a phase 2b study with the aim of identifying an optimal dosage of RMC The phase 2b study is also expected to enable the most efficient design of a subsequent pivotal phase 3 study. Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced further information regarding the development strategy for the investigational drug RMC An advisory meeting with the U. Food and Drug Administration FDA will be requested to explore dose optimization and the framework for a future registrational trial for the prevention of kidney injury in open-heart surgery.

Guard therapeutics

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Acute kidney injury is a large market. Guard Therapeutics announced that the U. Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of

Random tattoo sleeve

Learn more about the clinical development of RMC Speqta AB publ. Price SEK Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Financial Times Close. Cancel Continue. Show more US link US. The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin. The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. Click or tap a row for details. Show more Markets link Markets.

Acute kidney injury AKI affects millions of people annually and involves a rapid loss of kidney function because of various types of injuries to the kidneys. Without access to highly specialized medical care, mortality is often high and those who survive are at risk of suffering from chronic loss of kidney function, which in turn is associated with increased morbidity and reduced quality of life.

TradeDoubler AB. Guard Therapeutics Intrntnl AB publ. The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. Institutional shareholders Top holders Movers. Data as of Mar 01 Financial Times Close. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. Read more. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Financial calender Financial reports Share information Corporate governance General meetings. All content on FT. The company's Chief Medical Officer, Dr. Show more Companies link Companies. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC